Filing Overview
Registrant: Jupiter Wellness, Inc., despite the request metadata identifying BONK, INC. The Form 8-K was filed July 9, 2021, reporting events beginning July 8, 2021.
Business Context and Reporting Period
On July 8, 2021, Jupiter Wellness entered into an exclusive license agreement with Applied Biology, Inc. for Photocil™, a topical cream marketed for relief of psoriasis, vitiligo, and atopic dermatitis.
Material Agreement and Consideration
- The license covers specified copyrights, patents, technology, know-how, trademarks, and trade secrets related to Photocil™, including U.S. Patent No. 10,111,821.
- Jupiter received exclusive rights to manufacture, market, advertise, promote, and distribute Photocil™ for specified skin conditions.
- The initial term is five years from July 8, 2021, with automatic one-year renewals unless either party provides timely non-renewal notice.
- Consideration consists of $150,000 in cash and $150,000 worth of Jupiter common stock issued to Applied Biology.
- The stock issuance was reported under Item 3.02 as an unregistered sale of equity securities; the filing text does not provide the number of shares or issuance price.
Financial Metrics and Liquidity
This Form 8-K does not provide revenue, profit, cash flow, margins, debt, liquidity balances, or other operating financial metrics. The disclosed cash commitment is $150,000, plus $150,000 of common stock consideration.
Material Changes, Outlook, and Risks
The agreement expands Jupiter’s product portfolio and is intended to provide additional treatment options, including AM/PM or combination therapy. The filing does not provide revenue guidance, commercialization targets, expected financial impact, or management forecasts.
Key risks include the ability to successfully manufacture, market, distribute, and commercialize Photocil™, regulatory and intellectual-property considerations, product demand and clinical-market acceptance, and the Company’s ability to fund the cash consideration and related commercialization costs. The filing text does not describe contingencies, termination provisions beyond renewal mechanics, or guaranteed financial returns.
Important Facts to Verify
- Confirm the correct registrant: the supplied filing is for Jupiter Wellness, Inc., not BONK, INC.
- Review Exhibit 10.1 for the complete license terms, including termination rights, royalties, milestones, restrictions, and other obligations not included in the Form 8-K summary.
- Verify the number of common shares issued, valuation, and exemption relied upon for the unregistered stock issuance.
- Assess whether the license requires additional regulatory approvals, commercialization expenditures, or minimum performance commitments.
- Review subsequent filings for the agreement’s impact on revenue, expenses, cash usage, equity dilution, and product commercialization.